Eli Lilly's obesity drugs Mounjaro and Zepbound are driving explosive revenue growth, strengthening its dominance as demand ...
(Reuters) - Eli Lilly and Co's quarterly earnings beat Wall Street expectations, helped by surging growth of its Cymbalta depression treatment, and the company raised its 2012 profit outlook, due to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback